MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, CADL had -$13,724K decrease in cash & cash equivalents over the period. -$10,380K in free cash flow.

Cash Flow Overview

Change in Cash
-$13,724K
Free Cash flow
-$10,380K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-11,269 2,583
Depreciation expense
195 487
Impairment of fixed assets
1 82
Loss on the sale and disposal of fixed assets
-328 -11
Non-cash stock compensation expense
1,163 1,364
Non-cash lease expense
81 151
Non-cash interest expense
34 69
Change in fair value of warrant liability
-1,146 -20,572
Accretion of debt discount
21 76
Prepaid expenses and other current assets
-61 1,771
Other assets
40 -18
Accounts payable
-744 1,513
Accrued expenses
1,208 -1,243
Lease liability
-129 -275
Net cash used in operating activities
-10,236 -17,507
Purchase of fixed assets
144 34
Proceeds from the sale of fixed assets
27 -
Net cash used in investing activities
-117 -34
Proceeds from issuance of common stock in registered direct offering
-713 15,044
Proceeds from sale of common stock, net of issuance costs
0 5,038
Proceeds from option exercises
20 492
Principal payments on term loan
-2,500 -5,000
Payment of deferred debt issuance costs
178 -
Net cash provided by financing activities
-3,371 15,574
Net decrease in cash, cash equivalents and restricted cash
-13,724 -1,967
Cash and cash equivalents at beginning of period
102,920 -
Cash and cash equivalents at end of period
87,229 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Candel Therapeutics, Inc. (CADL)

Candel Therapeutics, Inc. (CADL)